Vaccinia Immune Globulin Intravenous (Human)
STN: BL 125109
Proper Name: Vaccinia Immune Globulin Intravenous (Human)
Manufacturer: Cangene Corp, License #1201
- treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination
- Eczema vaccinatum
- Progressive vaccinia
- Severe generalized vaccinia
- Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions
- Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard.
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.